GLP-1 Receptor Agonists for Neurodegenerative Diseases

Migration, Crosslink

📖

GLP-1 Receptor Agonists for Neurodegenerative Diseases

active

wiki page Created: 2026-04-02T07:18:57 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-glp1-receptor-agonists

📖 Wiki Page

therapeutic1073 wordssynced 2026-04-02

GLP-1 Receptor Agonists for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 Receptor Agonists for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Increased cAMP activates CREB</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>[mTOR](/entities/mtor) activation</td>
</tr>
<tr>
<td class="label">ERK1/2</td>
<td>Synaptic plasticity</td>
</tr>
<tr>
<td class="label">AMPK</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Inhibits caspase-3 activation</td>
</tr>
<tr>
<td class="label">Anti-inflammatory</td>
<td>Reduces TNF-α, IL-1β, IL-6</td>
</tr>
<tr>
<td class="label">Mitochondrial</td>
<td>Enhances PGC-1α expression</td>
</tr>
<tr>
<td class="label">Synaptic</td>
<td>Promotes spine formation</td>
</tr>
<tr>
<td class="label">[Autophagy](/entities/autophagy)</td>
<td>Enhances clearance of misfolded proteins</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">EVOKE</td>
<td>III</td>
</tr>
<tr>
<td class="label">EVOKE Plus</td>
<td>III</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NBI-818</td>
<td>I/II</td>
</tr>
<tr>
<

...

GLP-1 Receptor Agonists for Neurodegenerative Diseases

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 Receptor Agonists for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Increased cAMP activates CREB</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>[mTOR](/entities/mtor) activation</td>
</tr>
<tr>
<td class="label">ERK1/2</td>
<td>Synaptic plasticity</td>
</tr>
<tr>
<td class="label">AMPK</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Inhibits caspase-3 activation</td>
</tr>
<tr>
<td class="label">Anti-inflammatory</td>
<td>Reduces TNF-α, IL-1β, IL-6</td>
</tr>
<tr>
<td class="label">Mitochondrial</td>
<td>Enhances PGC-1α expression</td>
</tr>
<tr>
<td class="label">Synaptic</td>
<td>Promotes spine formation</td>
</tr>
<tr>
<td class="label">[Autophagy](/entities/autophagy)</td>
<td>Enhances clearance of misfolded proteins</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">EVOKE</td>
<td>III</td>
</tr>
<tr>
<td class="label">EVOKE Plus</td>
<td>III</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NBI-818</td>
<td>I/II</td>
</tr>
<tr>
<td class="label">PD MED</td>
<td>III</td>
</tr>
<tr>
<td class="label">exenatide-PD</td>
<td>II</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Half-life</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>2.4h</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>13h</td>
</tr>
<tr>
<td class="label">Dulaglutide</td>
<td>4.7h</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>165h</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Tirzepatide</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Retatrutide</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Survodutide</td>
<td>Boehringer</td>
</tr>
</table>

Glp 1 Receptor Agonists For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.

Overview

Mermaid diagram (expand to render)

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs originally developed for type 2 diabetes that have shown significant neuroprotective potential in neurodegenerative diseases["@hlscher2022"]. These agents cross the blood-brain barrier and activate GLP-1 receptors on [neurons](/entities/neurons) and glial cells, triggering intracellular signaling cascades that promote cell survival, reduce neuroinflammation, and enhance mitochondrial function. [@athauda2024]

The growing evidence for neuroprotective effects has led to extensive clinical testing in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions["@athauda2024"]. [@femminella2024]

Molecular Mechanisms

Receptor Signaling

GLP-1 receptors are Class B G protein-coupled receptors (GPCRs) expressed throughout the central nervous system, including the [hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), basal ganglia, and hypothalamus. Activation triggers multiple signaling pathways: [@zhang2023]

Neuroprotective Effects

Clinical Applications

Alzheimer's Disease

Semaglutide (Ozempic/Wegovy)

Semaglutide is a once-weekly [GLP-1 receptor](/entities/glp1-receptor) agonist being evaluated in large-scale Phase III trials for Alzheimer's disease:

The EVOKE trials represent the largest GLP-1 agonist program in AD to date, testing whether semaglutide can slow cognitive and functional decline in early AD patients.

Liraglutide (Victoza)

Liraglutide has been studied in multiple AD trials:

ELENA Trial: Phase II, 45 patients - Showed reduced amyloid plaques and improved cognition
TRAIL Trial: Phase II, 204 patients - Demonstrated slower cognitive decline
Mechanism: Promotes neurogenesis in hippocampus, reduces neuroinflammation

Dulaglutide (Trulicity)

The GIVE Phase II trial evaluated dulaglutide in early AD patients, completing in 2023 with results pending publication.

Parkinson's Disease

Exenatide (Byetta/Bydureon)

Exenatide has shown the most promise in PD:

Key Finding: In the Phase II study, patients receiving exenatide showed improvements in motor scores (MDS-UPDRS) that persisted even after a 12-week washout period, suggesting disease-modifying effects.

Liraglutide

Phase II trial in PD showed improvements in motor function and non-motor symptoms.

Comparative Pharmacology

Drug Properties

Neuroprotective Potency

Semaglutide shows the highest brain penetration and longest half-life, making it the leading candidate for neurodegenerative disease treatment.

Combination Therapy Potential

GLP-1 agonists may synergize with:

Anti-amyloid antibodies ([lecanemab](/entities/lecanemab), donanemab): Different mechanisms

Anti-[tau](/proteins/tau) therapies: Complementary targets

Neuroinflammation modulators: Enhanced effect

Mitochondrial protectors: Additive benefits

Safety and Tolerability

Adverse Events

Gastrointestinal: nausea (30-50%), vomiting (10-20%), diarrhea (15-25%)
Usually transient and manageable
Rare: pancreatitis, thyroid C-cell tumors (rodent studies)

Special Populations

Renal impairment: Dose adjustment may be needed
No significant hypoglycemia at neuroprotective doses
Cardiovascular: Generally safe, some benefit

Background

The study of Glp 1 Receptor Agonists For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data

Competitive Landscape

Other GLP-1 Agonists in Development

Market Analysis

GLP-1 agonists represent largest neurodegeneration pipeline
Semaglutide: Most advanced in AD
Expected: First GLP-1 approval in AD by 2027-2028

References

[Unknown, Hölscher C. GLP-1 analogues as treatment for Alzheimer's and Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35179723/)

Athauda D, Foltynie T, The glucagon-like peptide-1 analogue exenatide as a therapy for Parkinson's disease - a perspective (2024)

Femminella GD, Dioniso F, Ninan S, et al, Does GLP-1 receptor agonism represent a promising disease-modifying strategy for Alzheimer's disease? Brain (2024)

Zhang L, Zhang L, Li L, et al, Neuroprotective effects of GLP-1 receptor agonists in animal models of Parkinson's disease (2023)

Li Y, Li L, Holscher C, Incretin-based drugs for neurodegenerative diseases: mechanisms and therapeutic potential (2022)

Mulvaney CA, M H, Gray A, Exenatide once weekly for Parkinson's disease: systematic review and meta-analysis (2024)

Cereda E, Barichella M, Pekhal J, et al, GLP-1 receptor agonists in Parkinson's disease: the current evidence (2023)

Bussel I, Zhai W, Sun J, et al, Semaglutide for Alzheimer's disease: rationale and trial design (2024)

Paul KC, Sinsheimer JS, Cockburn N, et al, GLP-1 receptor agonists and neurodegenerative disease: a meta-analysis (2024)

Bluher M, MacDougald O, Banks A, GLP-1 agonists in clinical trials for neurodegeneration (2024)

Skovgard M, Tolbol KS, Simonsen AH, et al, The role of GLP-1 in neuroinflammation and neurodegeneration (2024)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[APOE-Dependent Autophagy Restoration](/hypothesis/h-51e7234f) — 0.73 · Target: MTOR
[Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — 0.79 · Target: SIRT1
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — 0.77 · Target: HCRTR1/HCRTR2
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — 0.76 · Target: ABCA1/LDLR/SREBF2
[Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — 0.76 · Target: NLRP3, CASP1, IL1B, PYCARD
[Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — 0.75 · Target: TFRC

Related Analyses:

[Metabolic reprogramming in neurodegenerative disease](/analysis/SDA-2026-04-02-gap-v2-5d0e3052) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄

📖 View canonical wiki page →

Related Entities

therapeutics-glp1-receptor-agonists-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-glp1-receptor-agonists-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-ee13058218fa
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-glp1-receptor-agonists-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

187

Outgoing

218

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

GLP-1 Receptor Agonists for Neurodegenerative Diseases

GLP-1 Receptor Agonists for Neurodegenerative Diseases

Introduction

GLP-1 Receptor Agonists for Neurodegenerative Diseases

Introduction

Overview

Molecular Mechanisms

Receptor Signaling

Neuroprotective Effects

Clinical Applications

Alzheimer's Disease

Semaglutide (Ozempic/Wegovy)

Liraglutide (Victoza)

Dulaglutide (Trulicity)

Parkinson's Disease

Exenatide (Byetta/Bydureon)

Liraglutide

Comparative Pharmacology

Drug Properties

Neuroprotective Potency

Combination Therapy Potential

Safety and Tolerability

Adverse Events

Special Populations

See Also

Background

External Links

Competitive Landscape

Other GLP-1 Agonists in Development

Market Analysis

References

💬 Discussion

📗 Cite This Artifact

GLP-1 Receptor Agonists for Neurodegenerative Diseases

GLP-1 Receptor Agonists for Neurodegenerative Diseases

Introduction

GLP-1 Receptor Agonists for Neurodegenerative Diseases

Introduction

Overview

Molecular Mechanisms

Receptor Signaling

Neuroprotective Effects

Clinical Applications

Alzheimer's Disease

Semaglutide (Ozempic/Wegovy)

Liraglutide (Victoza)

Dulaglutide (Trulicity)

Parkinson's Disease

Exenatide (Byetta/Bydureon)

Liraglutide

Comparative Pharmacology

Drug Properties

Neuroprotective Potency

Combination Therapy Potential

Safety and Tolerability

Adverse Events

Special Populations

See Also

Background

External Links

Competitive Landscape

Other GLP-1 Agonists in Development

Market Analysis

References

Related Hypotheses

💬 Discussion